After decades of procedures and millions upon millions of implant recipients, the FDA has formalized procedures that, among other things, now require patient notification of the potential risks and complications that come with breast augmentation surgery.
The move comes after several cases of breast implant-associated large cell lymphoma were reported in primarily European markets. Initially thought to be tied to the textured implants used mostly by European doctors, ...
continue reading...The Mayo Clinic and the American Society of Plastic Surgeons have both published information about a rare cancer with possible ties to breast implants as concerns continue to grow over breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL.
Initially, BIA-ALCL was thought to be a mostly European concern as the condition was generally associated with women who had received textured rather than smoothly surfaced ...
continue reading...The death toll formally attributed to breast implant-associated anaplastic large cell lymphoma now stands at 36, although it could be higher. Three new fatalities have occurred within the same six months and just weeks before the implants implicated in the deaths were set to be recalled.
The implants in question were made by Allergan prior to its acquisition by AbbVie. The Biocell textured ...
continue reading...
